The EMA CHMP positive option is for the Keytruda regimen to treat endometrial carcinoma and cervical cancer. Credit: Andrey Zhernovoy/Shutterstock.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological cancer indications.

The first positive opinion supports the use of KEYTRUDA along with carboplatin and paclitaxel, followed by the treatment alone, as a first-line therapy option for adults with primary advanced or recurrent endometrial carcinoma. These patients should be candidates for systemic therapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This recommendation is based on the KEYNOTE-868 trial, which showed significant improvement in progression-free survival with the KEYTRUDA-based regimen compared to placebo.

The second opinion recommends granting approval for KEYTRUDA plus chemoradiotherapy (CRT) to treat International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage III-IVA locally advanced cervical cancer in adult patients who did not receive definitive therapy previously.

This recommendation is based on the KEYNOTE-A18 trial, which demonstrated significant improvements in overall survival and progression-free survival when KEYTRUDA was combined with concurrent CRT.

See Also:

The European Commission will now review CHMP’s recommendations for marketing authorisation in the European Union (EU) with final decisions anticipated in the fourth quarter of 2024.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These would be the third and second indications for KEYTRUDA in endometrial and cervical cancers, respectively, in Europe.

Merck Research Laboratories global clinical development vice-president Dr Gursel Aktan stated: “At Merck, we are deeply committed to expanding the role of KEYTRUDA to improve outcomes for more patients facing difficult-to-treat gynaecologic cancers as we work to address the impact of women’s cancers around the world.

“These positive CHMP opinions bring us one step closer to providing new immunotherapy-based regimens to more patients with endometrial and cervical cancer in the European Union who may benefit. We look forward to the European Commission’s decisions.”